Aug 5, 2009 | 29
Pens and clipboards are so 1997. Attractive sales reps are so 2001. They might both still be commonplace, but pharmaceutical companies have also been sinking cash into a more obscured vehicle of persuasion: peer-reviewed medical journals.
One drug company—Wyeth, maker of the hormone therapy drugs Premarin and Prempro—paid for substantial ghostwriting of 26 medical research papers published in major scientific journals between 1998 and 2005, according to The New York Times. And these writers weren’t just polishing prose. They shaped the articles from start to finish.
Jan 31, 2009 | 3
A pioneering medical journal has fallen victim to the dramatic and wrenching changes that are overtaking the publishing industry: The Medscape Journal of Medicine (MJM), the first electronic-only open access general medical journal,* will no longer publish new papers, Editor in Chief George Lundberg and colleagues announced yesterday.
Open access is a movement to make studies available for free online, instead of charging taxpayers who funded the research (and others) to read them. The first for-profit open access publisher, BioMed Central (BMC), was founded in 2000 and launched BMC Biochemistry, its first journal, in July of that year. A BMC parent company made articles in existing journals open access in 1999.** BMC was sold to Springer last year. The Public Library of Science (PLoS), the first nonprofit open-access publisher, was also founded in 2000, but did not publish its first journal, PLoS Biology, until October 2003.
Deadline: Aug 31 2013
Reward: $100,000 USD
The Geoffrey Beene Foundation Alzheimer’s Initiative (GBFAI) is launching the 2013 Geoffrey Beene Global NeuroDiscovery Challenge whose
Deadline: Jul 15 2013
Reward: $5,000 USD
SciBX: Science-Business eXchange, a joint publication from the makers
Save 66% off the cover price and get a free gift!
Learn More >>X